Vaccine trial expanding to include young children in US, Canada

MORNING. DOUG: WE ARE FOLLOWING SOME BREAKING NEWS THIS TUESDAY MORNING. CAMBRIDGE-BASED MADERA HAS STARTED A NEW VACCINE CHILD -- TRIAL IN YOUNG CHILDREN. IT INVOLVES 7000 CHILD

One of the three companies currently administering COVID-19 vaccines in adults across the country has announced the expansion of a study testing their shot in children. In a news release issued Tuesday, Moderna announced its first participants in the KidCOVE study, the company's vaccine trial for children ages 6 months to 12 years. The study will aim to determine the safety, tolerability and effectiveness of two doses of a Moderna vaccine administered 28 days apart. Moderna is planning to enroll 6,750 participants in the U.S. and Canada. "We are pleased to begin this Phase 2/3 study of mRNA-1273 in healthy children in the U.S. and Canada and we thank NIAID and BARDA for their collaboration,” Stéphane Bancel, Chief Executive Officer of Moderna, wrote in the release. "We are encouraged by the primary analysis of the Phase 3 COVE study of mRNA-1273 in adults ages 18 and above and this pediatric study will help us assess the potential safety and immunogenicity of our COVID-19 vaccine candidate in this important younger age population."In the first part of the trial, each participant may receive one of two dose levels that will determine their dosage in the second part of the trial. Moderna plans to follow participants for a year after the second vaccination to determine effectiveness.

One of the three companies currently administering COVID-19 vaccines in adults across the country has announced the expansion of a study testing their shot in children.

In a , Moderna announced its first participants in the KidCOVE study, the company's vaccine trial for children ages 6 months to 12 years. The study will aim to determine the safety, tolerability and effectiveness of two doses of a Moderna vaccine administered 28 days apart.

Moderna is planning to enroll 6,750 participants in the U.S. and Canada.

"We are pleased to begin this Phase 2/3 study of mRNA-1273 in healthy children in the U.S. and Canada and we thank NIAID and BARDA for their collaboration,” Stéphane Bancel, Chief Executive Officer of Moderna, wrote in the release. "We are encouraged by the primary analysis of the Phase 3 COVE study of mRNA-1273 in adults ages 18 and above and this pediatric study will help us assess the potential safety and immunogenicity of our COVID-19 vaccine candidate in this important younger age population."

In the first part of the trial, each participant may receive one of two dose levels that will determine their dosage in the second part of the trial.

Moderna plans to follow participants for a year after the second vaccination to determine effectiveness.

��vlog